New Two-Pronged attack tested for Tough-to-Treat kidney cancer spread
NCT ID NCT07256223
Summary
This study is testing a new combination of two drugs, envafolimab and lenvatinib, as the first treatment for people with advanced kidney cancer that has spread to the liver. The goal is to see if this two-drug approach can effectively control the cancer and is safe for patients. It will enroll about 30 people who have not yet received any treatment for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER METASTASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.